Caroline Weltens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1336548/publications.pdf

Version: 2024-02-01

566801 264894 1,929 45 15 citations h-index papers

42 g-index 45 45 45 2436 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncology, The, 2015, 16, 47-56.	5.1	536
2	ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiotherapy and Oncology, 2015, 114, 3-10.	0.3	462
3	Internal mammary and medial supraclavicular lymph node chain irradiation in stage l–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1602-1610.	5.1	164
4	ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiotherapy and Oncology, 2016, 118, 205-208.	0.3	162
5	Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial. JAMA Oncology, 2017, 3, 42.	3.4	124
6	Breathing adapted radiation therapy in comparison with prone position to reduce the doses to the heart, left anterior descending coronary artery, and contralateral breast in whole breast radiation therapy. Practical Radiation Oncology, 2014, 4, 123-129.	1.1	57
7	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Annals of Oncology, 2012, 23, 2578-2584.	0.6	46
8	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	3.0	45
9	Side Effects 15 Years After Lymph Node Irradiation in Breast Cancer: Randomized EORTC Trial 22922/10925. Journal of the National Cancer Institute, 2021, 113, 1360-1368.	3.0	30
10	Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Research and Treatment, 2018, 167, 479-483.	1.1	27
11	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. Oncologist, 2019, 24, 165-171.	1.9	23
12	Risk factors for unplanned hospital reâ€admissions: a secondary data analysis of hospital discharge summaries. Journal of Evaluation in Clinical Practice, 2015, 21, 560-566.	0.9	16
13	Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival. Breast, 2017, 32, 18-25.	0.9	16
14	Reliability of clinical port films for measuring dose inhomogeneities in radiotherapy for head and neck tumours. Radiotherapy and Oncology, 1994, 30, 167-170.	0.3	15
15	A comparison of three different radiotherapy boost techniques after breast conserving therapy for breast cancer. Breast, 2015, 24, 391-396.	0.9	15
16	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	1.3	14
17	Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. European Journal of Surgical Oncology, 2019, 45, 550-559.	0.5	14
18	The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trial. Radiotherapy and Oncology, 2022, 172, 99-110.	0.3	14

#	Article	IF	Citations
19	Development and accuracy evaluation of a single-camera intra-bore surface scanning system for radiotherapy in an O-ring linac. Physics and Imaging in Radiation Oncology, 2019, 11, 21-26.	1.2	13
20	AÂcomparison of aÂbrachytherapy and an external beam radiotherapy boost in breast-conserving therapy for breast cancer: local and any recurrences. Strahlentherapie Und Onkologie, 2019, 195, 310-317.	1.0	13
21	Feasibility study of individualized optimal positioning selection for leftâ€sided whole breast radiotherapy: <scp>DIBH</scp> or prone. Journal of Applied Clinical Medical Physics, 2018, 19, 218-229.	0.8	10
22	Comparison of brachytherapy and external beam radiotherapy boost in breast-conserving therapy: Patient-reported outcome measures and aesthetic outcome. Strahlentherapie Und Onkologie, 2019, 195, 21-31.	1.0	10
23	Validation of the Web-Based IBTR! 2.0 Nomogram to Predict for Ipsilateral Breast Tumor Recurrence After Breast-Conserving Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1477-1484.	0.4	9
24	PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study. Supportive Care in Cancer, 2019, 27, 4123-4132.	1.0	9
25	Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical featuresÂin invasive micropapillary breast carcinoma with long-term outcomes. Breast Cancer Research and Treatment, 2020, 184, 985-998.	1.1	9
26	Spirometer-guided breath-hold breast VMAT verified with portal images and surface tracking. Radiotherapy and Oncology, 2021, 157, 78-84.	0.3	9
27	Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3. ESMO Open, 2021, 6, 100203.	2.0	8
28	Evaluation of a breast cancer nomogram to predict ipsilateral breast relapse after breast-conserving therapy. Radiotherapy and Oncology, 2016, 119, 45-51.	0.3	7
29	Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study. Breast Cancer Research and Treatment, 2018, 168, 189-196.	1.1	7
30	Standardised mortality ratios as a user-friendly performance metric and trigger for quality improvement in a Flemish hospital network: multicentre retrospective study. BMJ Open, 2019, 9, e029857.	0.8	7
31	Intra-fraction motion monitoring during fast modulated radiotherapy delivery in a closed-bore gantry linac. Physics and Imaging in Radiation Oncology, 2021, 20, 51-55.	1.2	7
32	Boost delineation in breast radiation therapy: Isotropic versus anisotropic margin expansion. Practical Radiation Oncology, 2016, 6, e243-e248.	1.1	6
33	Reply to Dr Altundag from the authors of †Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival†Breast, 2017, 36, 103.	0.9	6
34	Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2â ⁻ early breast cancer. Modern Pathology, 2021, 34, 1297-1309.	2.9	5
35	Is the use of a preoperative computed tomography beneficial to reduce the interobserver variability of the CTVboost delineation for breast radiation therapy?. Practical Radiation Oncology, 2016, 6, 376-382.	1.1	4
36	Development of a normal tissue complication probability model for late unfavourable aesthetic outcome after breast-conserving therapy. Acta Oncol \tilde{A}^3 gica, 2018, 57, 916-923.	0.8	3

#	Article	lF	Citations
37	Technical Note: Development of 3Dâ€printed breast phantoms for endâ€toâ€end testing of whole breast volumetric arc radiotherapy. Journal of Applied Clinical Medical Physics, 2020, 21, 315-320.	0.8	2
38	Tumour bed boost radiotherapy for women after breast conserving surgery. The Cochrane Library, $2015, , .$	1.5	1
39	Validation of a normal tissue complication probability model for late unfavourable aesthetic outcome after breast-conserving therapy. Acta Oncológica, 2019, 58, 448-455.	0.8	1
40	Quality Indicators in Vascular Surgery: Toward a National Consensus on 20 Quality Indicators in Belgium. Annals of Vascular Surgery, 2021, 71, 237-248.	0.4	1
41	Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1041-1048.	1.2	1
42	Validation of a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer. Breast, 2022, 64, 29-34.	0.9	1
43	P695Impact of atrial fibrillation on 10y all-cause mortality in curatively treated breast cancer patients. European Heart Journal, 2019, 40, .	1.0	O
44	Indications for individual internal mammary node irradiation – Authors' reply. Lancet Oncology, The, 2021, 22, e41.	5.1	0
45	SU-E-T-562: Do the Differences Between Photon Dose Distributions in the Breast Have Significant Impact On the Parameters of Radiobiological Models?. Medical Physics, 2013, 40, 335-335.	1.6	O